An East Bay startup is looking to create antibody drugs at the source: humans.
Infinimmune, with six people and a fresh $12 million seed round, is made up of veterans of 10x Genomics Inc., the Pleasanton-based company that pioneered single-cell sequencing technology. But the startup's founders want to turn those types of tools into an engine for finding and developing drugs made from human antibodies.
Those Y-shaped blood proteins are produced in response to specific invaders in the body.
What if, Infinimmune's founders said, we plucked out truly human antibodies that already may be focused on diseases?"We're harnessing antibodies that already effectively work and keep their safety profile," McDonnell said. What's more, he said, using human antibodies could take laborious steps out of a production process that today includes using Chinese hamster ovary cells as the preferred"factory" for making therapeutic humanized monoclonal antibodies."The tools to look into this are complex, extremely new and difficult to deploy and build," McDonnell said.
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
출처: SFBusinessTimes - 🏆 78. / 68 더 많은 것을 읽으십시오 »
출처: SFBusinessTimes - 🏆 78. / 68 더 많은 것을 읽으십시오 »
출처: SFBusinessTimes - 🏆 78. / 68 더 많은 것을 읽으십시오 »